Cosmo Pharmaceuticals announces preliminary end result of its tender offer for BioXell

03-Mar-2010 - BioXell S.p.A. announced that, on 26 February 2010, which is the end of the additional acceptance period, Cosmo Pharmaceuticals S.p.A. holds 98.96 percent of the shares, respectively voting rights of BioXell S.p.A, Milano. Until the end of the additional acceptance period on 26 February 2010, ...

Cosmo holds 94.7% of BioXell voting rights and shares

11-Feb-2010 - BioXell S.p.A. announced that, on 8 February 2010, which is the end of the offer period, Cosmo Pharmaceuticals S.p.A. holds 94.773 percent of the shares, respectively voting rights of BioXell S.p.A, Milano. This announcement is made in connection with the recommended public tender offer of Cosmo ...

BioXell Supports Planned Acquisition by Cosmo Pharmaceuticals

19-Nov-2009 - BioXell S.p.A. announced that it has entered into a transaction agreementwith Cosmo Pharmaceuticals S.p.A., under which the parties have agreed on the terms and conditions according to which Cosmo will launch a public tender offer (Offer) for all outstanding shares of BioXell. Pursuant to the ...

BioXell announces change in management

09-Sep-2009 - BioXell S.p.A. announced the termination on the basis of a mutual agreement of the employment relationship with Bertrand Lehuu, Chief Business Officer. His responsibilities will be taken over by the company's Chief Executive Officer, Niels Ackermann. "I would like to thank Bertrand Lehuu for ...

BioXell announces re-election of Thomas Szucs as Chairman of its Board of Directors

28-May-2009 - BioXell S.p.A. announced that the members of the Board of Directors unanimously re-elected Prof. Thomas Szucs as Chairman. Prof. Szucs has been the Chairman of BioXell's Board of Directors since November 1st, 2006, and was re-elected as a Director of the Company at the Annual General meeting on ...

BioXell announces restructuring following review of portfolio

04-May-2009 - BioXell S.p.A. announced the initiation of a redundancy procedure (Procedura di Mobilità according to Sec. 4 and 24 of Italian Law 223/1991) in order to align its internal organization and resources as a result of BioXell's reduced product pipeline and the relating research & development ...

BioXell S.p.A. announces change in management

29-Jul-2008 - BioXell S.p.A. announced that Enrico Colli, Chief Medical Officer, has resigned from the Company for personal reasons in order to pursue a career at a large pharmaceutical organization. He is expected to leave the Company at the end of September. Francesco Sinigaglia, Chief Executive Officer, ...

BioXell announces start of Phase IIa trial of Elocalcitol in Male Infertility

20-Nov-2007 - BioXell S.p.A. announced the enrollment of the first patient in its Phase IIa trial of Elocalcitol in male infertility, a widespread condition currently with no effective treatment. The trial is designed to test the ability of Elocalcitol to improve sperm quality in infertile male patients. ...

BioXell confirms strong potential of Elocalcitol

19-Oct-2007 - At its second annual R&D Day in Zurich, BioXell presented further analysis of its Phase IIb trial data in Benign Prostatic Hyperplasia (BPH), confirming that Elocalcitol has strong potential to become a new first-line monotherapy for BPH. Current BPH first-line therapies consist of combinations ...

BioXell announces positive Phase IIb results for Elocalcitol in Benign Prostatic Hyperplasia

Primary endpoint met - Elocalcitol highly effective in arresting prostate growth

15-Oct-2007 - BioXell S.p.A. announced top-line results of its Phase IIb trial of Elocalcitol in Benign Prostatic Hyperplasia (BPH). The primary endpoint was met with a high degree of statistical significance, with Elocalcitol effectively arresting prostate growth. Elocalcitol also showed relevant effects on ...